BT 11

Drug Profile

BT 11

Alternative Names: BT-11

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Landos Biopharma
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Inflammation mediator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Crohn's disease; Ulcerative colitis

Most Recent Events

  • 03 Oct 2017 Landos Biopharma has patent protection for BT 11 in USA (Landos Biopharma, September 2017)
  • 03 Oct 2017 Preclinical pharmacodynamics data in Crohn's disease released by Landos Biopharma (Landos Biopharma pipeline, September 2017)
  • 03 Oct 2017 Landos Biopharma plans a phase Ia, IIa and III trials for Crohn's disease (Landos Biopharma Pipeline, September 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top